secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001171843-25-003174
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose's TUS+VEN+AZA triplet data selected for oral presentation at EHA 2025 Congress
--------------------------------------------------------------------------------

- Data from TUSCANY Phase 1/2 trial of tuspetinib (TUS) + venetoclax + azacitidine in newly diagnosed AML accepted for oral presentation at EHA 2025 (June 12-15, Milan).
- Oral presentation will include updated safety, complete remission, and MRD data at 40 mg and 80 mg dose levels with longer follow-up.
- Prior data showed safety and complete remissions across diverse mutations including TP53-mutated and FLT3-wildtype patients.
- TUS+VEN+AZA is being developed as mutation-agnostic frontline therapy for AML patients ineligible for induction chemotherapy.
- Anticipated enrollment of 18-24 patients in TUSCANY trial by mid-late 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184325003174/0001171843-25-003174-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184325003174/f8k_051425.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-003174

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer